Treatment of advanced non-small cell lung cancer: Chemotherapy with or without cisplatin?

Annals of Oncology

Volumn 17, Issue SUPPL. 2, 2006, Pages

  Gebbia, V ^a   Oniga, F ^b   Agueli, R ^a   Paccagnella, A ^b  

^a UNIVERSITY OF PALERMO   (Italy)

^b Venice Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; IFOSFAMIDE; MESSENGER RNA; NAVELBINE; PACLITAXEL; RIBONUCLEOTIDE REDUCTASE;

ADVANCED CANCER; ALOPECIA; ANEMIA; APPETITE DISORDER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DNA ADDUCT; DOSE RESPONSE; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INFUSION; DRUG TARGETING; DRUG TOLERABILITY; EXCISION REPAIR; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GENE EXPRESSION; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR BIOPSY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; HUMANS; LUNG NEOPLASMS; MEDICAL ONCOLOGY; NEOPLASM STAGING; PLATINUM COMPOUNDS; PROGNOSIS;

EID: 33645813402     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj933     Document Type: Article

References (38)

1. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br J Med 1995; 311: 899-909.
2. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330-353.
3. Bunn PA. Chemotherapy for advanced non-small cell lung cancer. Who, what, when, why? J Clin Oncol 2002; 20 (Suppl. 18): 23s-33s.
4. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small cancer. N Engl J Med 2002; 346: 92-98.
5. Kelly K, Crowley J, Bunn PA et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
6. Fossella F, Pereira RJ, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combination versus vinorelbine plus cisplatin for advanced non-small cell lung cancer. The TAX 326 Study Group. J Clin Oncol 2003; 21: 3016-3024.
7. Ettinger D, Johnson D. Update. NCCN Small Cell and Non-Small Cell Lung Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2005; 3 (Suppl 1): S17-S21.
8. Bunn PJ, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 1998; 5: 1087-1100.
9. Thongprasert S, Sanuganmitra P, Juthapan N. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSc) versus BSC plus chemotherapy. Lung Cancer 1999; 24: 17-24.
10. Rossi A, Maione P, Gridelli C. Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients. Exp Opin Drug Saf 2005; 4: 1051-1067.
11. Gridelli C, Ardizzoni A, Le Chevalier T et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol 2004; 15: 419-426.
12. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-2597.
13. Socinski MA: Cytotoxic chemotherapy in advanced non-small cell lung cancer. A review of standard treatment paradigms. Clin Cancer Res 2004; 10: 4210S-4214S.
14. Soria JC, Le Chevalier T. Is cisplatin still the best platinum compound in non-small-cell lung cancer? Ann Oncol 2002; 13: 1515-1517.
15. Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17: 409-422.
16. Rosell R, Gatzemeier U, Betticher DC et al. Phase III randomised trial comparing paclitaxel/carboplatin versus paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Ann Oncol 2002; 13: 1539-1549.
17. Fossella F, Pereira RJ, von Panel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combination versus vinorelbine plus cisplatin for advanced non-small cell lung cancer. The TAX 326 Study Group. J Clin Oncol 2003; 21: 3016-3024.
18. Hotta K, Matsuo K, Ueoka H et al. Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004; 22: 3852-3859.
19. Tiseo M, Boni L, Ardizzoni A. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: Does cisplatin versus carboplatin make a difference? J Clin Oncol 2005; 23: 6276-6277.
20. Piedbois P, Buyse M. Meta-analyses based on abstracted data: A step in the right direction, but only a first step. J Clin Oncol 2004; 22: 3839-2841.
21. Bunn PA. Platinums in lung cancer: Sufficient or necessary? J Clin Oncol 2005; 23: 2882-2883.
22. Androulakis N, Georgoulias V. NSCLC - platinum or not. Lung Cancer 2005; 47: 380-383.
23. Schiller JH. Platin or no platin? That is the question. J Clin Oncol 2003; 21: 3009-3010.
24. Gridelli C, Gallo C, Shepherd FA et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3025-3034.
25. Alberola V, Camps C, Provencio M et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus non-platinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group Phase III randomized trial. J Clin Oncol 2003; 21: 3207-3213.
26. Smit EF, van Meerbeeck JP, Lianes P et al. Three-arm randomized study of two cisplatin based regimens and paclitaxel plus gemcitabine in advanced non small cell lung cancer: A phase III trial of the European organization for research and treatment of cancer. Lung Cancer Group EORTC 08975. J Clin Oncol 2003; 21: 3909-3917.
27. Georgoulias V, Ardavanis A, Tsiafaki X et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non small cell lung cancer: A phase III randomized trial. J Clin Oncol 2004; 23: 2937-2945.
28. Kosmidis P, Mylonakis N, Nicolaides C et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: A phase III randomized trial. J Clin Oncol 2002; 20: 3578-3585.
29. Tan EH, Szczesna A, Krzakowski M et al. Randomized study of vinorelbine-gemcitabine versus vinorelbine-carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 2005; 49: 233-240.
30. D'Addario G, Pintilie M, Leighl NB et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23: 2926-2936.
31. Barlesi F, Pujol J, Daurès J. Should chemotherapy for advanced non-small-cell lung cancer (NSCLC) be platinum-based? A literature-based meta-analysis of randomized trial. Proc Am Soc Clin Oncol 2005; 23: 673s (Abstr 7213).
32. Yamamoto N, Fukuoka M, Negoro SI et al. Randomized phase II study of docetaxel/cisplatin vs. docetaxel/irinotecan in advanced non-small cell lung cancer: A West Thoracic Oncology Group Study (WJTOG 9803). Br J Cancer 2004; 90: 87-92.
33. Rigas JR, Carey M, Cole B et al. Multicenter web-based phase III study to test the survival equivalence of non platinum-based (NPB) vs platinum-based (PB) therapy for advanced non-small cell lung cancer (NSCLC). The Dartmouth NPB Chemotherapy Trial (DO112), Proc Am Soc Clin Oncol 2004; 23: 631 (Abstr 7071).
34. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362-372.
35. Rosell R, Danenberg KD, Alberola V et al. Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Cancer Res 2004; 10: 1318-1325.
36. Isla D, Sarries C, Rosell R et al. Single nucleotide polymorphism and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004; 15: 1194-1203.
37. Gurubhagavatula S, Liu G, Park S et al. XDP and XRCC1 genetic polymorphism are prognostic factor in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22: 2594-2601.
38. Rosel R, Cobo M, Isla D et al. ERCC1 mRNA-based randomized phase III trial of docetaxel (doc) doublets with cisplatin (cis) or gemcitabine (gem) in stage IV non-small-cell lung cancer (NSCLC) patients (p). Proc Am Soc Clin Oncol 2005; 23: 621s (Abstr 7002).